Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA, RSV and Pfizer
FDA approves Pfizer's RSV shot Abrysvo for all at-risk adults
While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to determine how much advantage will be gained from the nod as the Centers for Disease Control (CDC) will have to sign off on Abvrysvo's use in the wider age group.
FDA expands Pfizer’s RSV vaccine label to include all high-risk adults
Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.
PFE Gets FDA Nod for Expanded Use of RSV Vaccine Abrysvo
Pfizer Inc. PFE announced that the FDA has granted approval for the expanded use of its respiratory syncytial virus (RSV) vaccine, Abrysvo, in adults aged 18-59 years. The vaccine has been approved for the prevention of lower respiratory tract disease (LRTD) caused by RSV in patients aged 18-59 years who are at increased risk of the disease.
Pfizer’s RSV vaccine cleared by FDA for use in some younger adults
Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people eligible for vaccination with the shot.
FDA Approves Abrysvo RSV Vaccine for Adults at Increased Risk
Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.
FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years
Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals to safeguard infants from birth.
New FDA approval for Pfizer’s RSV vaccine Abrysvo
The US Food and Drug Administration (FDA) yesterday approved Abrysvo (respiratory syncytial virus vaccine). Developed and marketed by US pharma giant Pfizer, the vaccine is now authorized for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV.
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine,
Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population
Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age. Tuesday’s label expansion covers younger adults who are deemed at higher risk of RSV-related lower respiratory tract disease.
FDA OKs Pfizer’s RSV vaccine for some adults under 60
On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for people 18 to 59 who are more vulnerable to the virus.
FDA Expands Approval of RSV Vaccine Abrysvo to Include All At-Risk Adults
The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in high-risk adults ages 18 to 59 years, Pfizer announced on Tuesday.
FiercePharma
1d
GSK answers Pfizer's RSV approval with data targeting matching nod in younger adults
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
Hosted on MSN
3d
Is Pfizer's Attractive Valuation Enough to Invest in the Stock?
Drug giant Pfizer PFE is trading quite cheap after its stock took a beating last year once the pandemic ended. The stock is ...
3d
Mixed Prospects and Uncertainty Lead to Hold Rating for Pfizer Amid COVID-19 Revenue Fluctuations
Analyst Mohit Bansal from Wells Fargo maintained a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at $30.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Grateful Dead bassist dies
DOJ reaches settlement
DNA tests identify skull
Kristy now Category 5
Murder-for-hire plot arrest
Dismissal of charge upheld
Exonerated after 22 years
Hit w/ discrimination claims
CO ballots to be reexamined
ABC News icon Jarriel dies
Strike kills 3 journalists
AI firm sued over suicide
Louisiana forces relocation
E. coli infections rise to 75
SC teen voting glitch
Madigan corruption trial
Announces layoffs, jet sales
New student loan relief plan
Apology for past US policy
Browns sue city of Cleveland
Recalls chicken products
Phones hacked by China?
VA voter roll purge blocked
Gaza peace talks to resume?
MO AG to probe Google
Israel strikes back at Iran
World's most valuable firm
NASA astronaut hospitalized
Approves Iterum's treatment
Jeffries pleads not guilty
Won't endorse candidates
Feedback